Yuh-Min Chen Taiwan

Medical School

1978–1985   National Yang-Ming Medical College
1983–1985   Intern, Taipei Veterans General Hospital

Postgraduate Training

  • 1987–1989   Resident, Medical Department, Uan-Chyan Veterans Hospital, Taiwan
  • 1989–1992   Resident, Chest Department, Taipei Veterans General Hospital
  • 1992–1993   Chief Resident, Chest Department, Taipei Veterans General Hospital
  • 1993–1994   Fellow, Chest Department, Taipei Veterans General Hospital
  • 1993–1995   Fellow, Cancer Clinical Research Center, Institute of Biomedical Sciences, Academia Sinica
  • 1996–1997   Visiting Fellow, National Cancer Institute, National Institutes of Health, USA
  • 1994–1998   Ph.D., Institute of Clinical Medicine, National Yang-Ming University

Academic Appointment

  • 1991–present   Board certified, Internal Medicine
  • 1992–1997   Clinical Lecturer, Medical Department, National Yang-Ming University
  • 1993–present   Board certified, Chest Medicine
  • 1994–2026   Attending Physician, Department of Chest Medicine, Taipei Veterans General Hospital
  • 1995–present   Board certified, Medical Oncology
  • 1997–1999   Clinical Assistant Professor, School of Medicine, National Yang-Ming University
  • 2004–2012   Clinical Associate Professor, School of Medicine, National Defense University
  • 1998–2008   Adjunct Attending Physician, Institute of Cancer Research, National Health Research Institutes
  • 1999–2002   Assistant Professor, School of Medicine, National Yang-Ming University
  • 2002–2013   Associate Professor, School of Medicine, National Yang-Ming University
  • 2008/8–2013   Clinical Professor, Taipei Medical University
  • 2013–2022   Professor, College of Medical Science and Technology, Taipei Medical University
  • 2015/9/1–2020/1/15   Chief, Division of General Chest Medicine, Department of Chest Medicine, Taipei Veterans General Hospital, Taipei
  • 2016–2026   Chairman, Thoracic Oncology Multidisciplinary Team, Taipei Veterans General Hospital, Taipei
  • 2016/2/1–present   Professor, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei
  • 2020/01/16–2026/01/15   Head, Department of Chest Medicine, Taipei Veterans General Hospital, Taipei
  • 2026/3/2–   Head, Clinical Research Center, Shin Kong Wu Ho-Su Memorial Hospital, Taipei

Professional Interests and Specialties

  1. Internal Medicine
  2. Pulmonary and Critical Care Medicine
  3. Medical Oncology, especially Thoracic Oncology
  4. Cell Biology and Molecular Biology
  5. Tumor Immunology
  6. Chemotherapy
  7. Targeted Therapy
  8. Immunotherapy

Professional Societies

  • Member, European Society of Clinical Oncology
  • Member, American Society of Clinical Oncology
  • Member, International Association for the Study of Lung Cancer
  • Member, Asia-Pacific Society of Respirology Research Committee, 2020–present
  • Fellow, American College of Chest Physicians
  • Member, Society of Internal Medicine (Taiwan)
  • Member, Society of Ultrasound in Medicine (ROC)
  • Member, Taiwan Clinical Oncology Society
  • Member, Taiwan Cancer Society
  • Member, Taiwan Society of Respiratory and Intensive Care Medicine
  • Member, Chinese Medical Association (Taipei)
  • Member, Taiwan Lung Cancer Society
  • Member, Asia-Pacific Society of Respirology
  • Member, European Respiratory Society
  • Secretary, Taiwan Clinical Oncology Society, 1994–2001
  • Secretary General, Taiwan Lung Cancer Society, 2000–2008, 2009–2012
  • Secretary General, Taiwan Clinical Oncology Society, 2001–2007
  • Secretary General, 15th Taiwan Jointed Cancer Conference, May 2018, Taipei, Taiwan
  • President, Taiwan Clinical Oncology Society, 2007–2013
  • Audit, Taiwan Society of Palliative Medicine, 2008–2010
  • Director, Chinese Oncology Society, 2011–2013
  • Director, Taiwan Clinical Oncology Society, 2013–present
  • Member of Scientific Committee, 12th, 13th, and 14th World Conference on Lung Cancer, IASLC, 2007, 2009, 2011
  • Section Chair, 13th and 14th World Conference on Lung Cancer, IASLC, 2009 and 2011
  • Co-Chair, Organizing Committee, Taiwan Joint Cancer Conference, 2000–2013, 2016, 2017, 2019, 2020
  • Chair, Organizing Committee, Annual Meeting of Cross-Strait Academic Conference on Oncology, 2007–2014
  • Vice-Chair, Organizing Committee, bi-annual meeting of Chinese Anti-Cancer Society, 2007–2013
  • Organizing Committee, Round Asia Oncology Forum (RAOF) 2012, Taipei, Taiwan, 2012/8/31–2012/9/2
  • Committee member, Avastin global advisory board meeting, 15th World Conference on Lung Cancer (WCLC 2013), Sydney, Australia, October 31, 2013
  • Chair, Iressa Asia area advisory board meeting, Taipei, Taiwan, March 8, 2014
  • President, Taiwan Lung Cancer Society, 2015/05/08 – 2021/08/26
  • Chair, TLCS and IASLC Lung Cancer Symposium, October 28–29, 2017, Taipei, Taiwan
  • Chair, 23rd Taiwan Jointed Cancer Conference, May 5–6, 2018, Taipei, Taiwan
  • Committee member, 2nd Expanded Asia NSCLC Adboard Meeting for Afatinib, Taipei, Taiwan, October 6, 2018
  • Chair, 2020 Taiwan Lung Cancer Society International Symposium on Treatment Advances in Lung Cancer, Taipei, January 1–12, 2020
  • Councillor, Asia-Pacific Society of Respirology, 2024/Aug – present
  • President, The 9th Asia-Pacific Region Conference of the International Union Against Tuberculosis and Lung Disease and the 2024 Summer Meeting of the Taiwan Society of Pulmonary and Critical Care Medicine, 2024/4/26–2024/4/29, Taipei, Taiwan
  • President, The 10th Asian Pacific Congress on Bronchology and Interventional Pulmonology and the 2025 Summer Meeting of the Taiwan Society of Pulmonary and Critical Care Medicine, 2025/6/20–2025/6/22, Taipei, Taiwan
  • President, Taiwan Society of Pulmonary and Critical Care Medicine, 2023/12/14 – present
  • Secretary General, Asian Pacific Society of Respirology, 2025 Dec –
Job Title
Head
Faculty / Department / Division
Department of Clinical Research Center
Institution / Organisation
Shin Kong Wu Ho-Su Memorial Hospital

20 November 2026, Friday

Time Session
11:00
12:00
David Lam Chi-Leung Chairperson Hong Kong
Ernest Mau Ern Poh Chairperson Malaysia
  • Ren Yuan Speaker Canada
    AI Radiomics for the Early Detection of Lung Cancer Background: Lung cancer remains the leading cause of cancer-related mortality in Canada. Low-dose computed tomography (LDCT) screening frequently detects small or ground-glass opacity nodules that are challenging to assess for malignancy. This study aimed to develop a radiomics-based machine-learning model to predict the future malignant behaviour of these difficult nodules. Materials and Methods: Small nodules were drawn from three lung cancer screening datasets: PanCan (n=2,085 participants; N=10,381 nodules), ILST (n=1,082 participants; N=2,389 nodules), and DLCS (n=1,373 participants; N=2,009 nodules). A self-attention deep-learning model was trained for nodule segmentation, and axial masks were reconstructed into three-dimensional core nodule masks. Radiomics features were extracted from four discrete regions: the nodule core and surrounding regions, including core-plus-edge, shell, and shell-without-blood-vessel masks. Machine-learning models were developed and compared with the Brock model. Results: At a low false-positive rate of 10%, the ML-radiomics models demonstrated superior sensitivity to the Brock model across all nodule types in the external validation set. Both approaches identified malignant nodules at baseline that would not have otherwise received interventional management and predicted malignancy up to 2 years before clinical confirmation. Conclusion: A pipeline integrating deep-learning segmentation with ML-radiomics can accurately classify subcentimetre nodules up to approximately 2 years before clinical confirmation of malignancy in lung cancer screening. Keywords: Lung Cancer, LDCT Screening, Radiomics, Machine Learning, Deep Learning
  • Chong Kin Liam Speaker Malaysia
    Lung cancer is a major health problem in the in the Asia-Pacific, with the region accounting for over 60% of global lung cancer diagnoses and deaths. Compared to Western counterparts, lung cancer in Asia exhibits distinct and unique characteristics. Key differences between lung cancer in Asia and outside Asia include a much higher prevalence in never-smokers, younger age of onset, and significantly higher rates of EGFR mutations (30-40% vs. 7-15% in the West). Over 30% of Asian lung cancer patients are never-smokers, with that number rising to over 50% in East Asian women. This is significantly higher than in Western countries. Asian patients have a much higher prevalence of EGFR mutations (30-40%) compared to Caucasian patients (7-15%). Conversely, KRAS mutations which are commonly smoking-related are less frequent in Asian patients (8-10%) than in Western populations (20-30%). While smoking is still a major cause, especially in men (half of the world's smokers live in Asia), never-smoker cases are highly driven by indoor air pollution (biomass fuel), ambient particulate matter (PM2.5), and passive smoking. Asian patients are generally diagnosed at a younger age, with early-onset lung cancer incidents rising, particularly in China, India, and Indonesia. Adenocarcinoma is the most common histological subtype in Asia, often appearing as ground-glass opacities. Asian patients tend to have a better prognosis. However, access to molecular diagnostics and newer, more effective treatments varies significantly between high-income countries (e.g., Japan, South Korea, Australia) and low-to-middle-income countries in the region.
  • Yuh-Min Chen Speaker Taiwan
    "Background Lung cancer is the leading cause of cancer-related mortality in the Asia Pacific (APAC) region, accounting for approximately 60% of global cases. The demographic of lung cancer in this region is shifting, with increasing incidence among younger individuals, non-smokers, and women. Driven by diverse risk factors including air pollution, occupational hazards, genetic predisposition, and household cooking fumes, there is a pressing need for personalized approaches to screening, diagnosis, and treatment. Early Detection & Screening Low-dose computed tomography (LDCT) screening has been instrumental in shifting detection toward early-stage disease. While global trials primarily focus on heavy smokers, regional data indicates that genetic factors play a critical role. A nationwide screening program in Taiwan demonstrated that individuals with a family history of lung cancer have a higher detection rate of early-stage disease (89.6%) compared to heavy smokers (66.1%). This targeted screening approach has led to a significant stage shift and a projected 53% reduction in lung cancer mortality. Targeted Therapy & Immunotherapy Recent phase III trials evaluating targeted therapies (such as osimertinib, amivantamab plus lazertinib, and lorlatinib) and immunotherapies (including pembrolizumab and neoadjuvant nivolumab) show that clinical efficacy and toxicity profiles in Asian cohorts are highly consistent with global populations. Subgroup analyses from landmark trials, including FLAURA2, MARIPOSA, KEYNOTE-189, and CheckMate 816, confirm that APAC patients derive comparable progression-free survival (PFS), overall survival (OS), and pathological complete response (pCR) benefits from these advanced treatment modalities. Conclusions & Future Challenges Despite the biological efficacy of advanced treatments mirroring global outcomes, the APAC region faces unique, systemic challenges. Wide regional variations in healthcare infrastructure, drug pricing, and reimbursement criteria—along with underrepresentation in global clinical trials—create significant disparities in early diagnosis and treatment access. Overcoming these socio-economic barriers and optimizing management strategies in resource-limited settings remain the primary challenges for improving lung cancer survival rates across the Asia Pacific region. "
  • Q&A
Ballroom 3, Lower Ground Floor